MOTS-C 40MG

Primary Pathway: Folate → AICAR → AMPK ("Master Metabolic Switch")

MOTS-c inhibits the folate cycle at 5-methyltetrahydrofolate (5Me-THF), blocking de novo purine biosynthesis. This leads to accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), which mimics AMP and directly activates AMPK.[1]

1. MOTS-c → inhibits folate cycle (5Me-THF)
2. Blocked purine synthesis → AICAR accumulation
3. AICAR (AMP mimetic) → direct AMPK activation
4. AMPK → ACC phosphorylation → fatty acid oxidation
5. AMPK → GLUT4 translocation → enhanced glucose uptake

Direct Binding Partners

Target	Binding Domain	Functional Consequence
CK2α	Cationic tail (¹³RKLR¹⁶)	Skeletal muscle insulin sensitization; K14Q polymorphism reduces this binding[7]
Raptor (mTORC1)	Hydrophobic core (⁸YIFY¹¹)	Allosteric mTORC1 inhibition → shifts T-cell differentiation from Th1 to FOXP3+ Tregs[8]
Nrf2 (nuclear)	Direct chromatin binding	Nuclear translocation under stress → ARE → antioxidant gene expression (~1,000 genes)[3]

Nuclear Translocation

Under metabolic stress (glucose restriction, oxidative stress), MOTS-c translocates from mitochondria/cytoplasm to the nucleus. It lacks a canonical nuclear localization signal (NLS) — instead relying on its hydrophobic core for entry. Once nuclear, it binds chromatin at ARE via Nrf2 transcription factor to regulate antioxidant gene expression.[3]

SIRT1/PGC-1α Pathway

MOTS-c increases intracellular NAD+ → activates SIRT1 → PGC-1α deacetylation → mitochondrial biogenesis and anti-inflammatory cytokine regulation.[6]

MAPK/ERK (Tissue-Dependent)

• Adipose tissue: Activates ERK → UCP1/PGC-1α → thermogenesis/browning of white fat[9]
• Inflammation: Inhibits ERK/JNK/p38 → suppresses NF-κB[10]

TGF-β/SMAD (Bone)

In osteoblasts: upregulates TGF-β1/2 and SMAD7 → Type I collagen synthesis → osteogenic differentiation.[11]

vs. Related Compounds

Compound	Origin	Key Difference
MOTS-c	mtDNA 12S rRNA (MT-RNR1)	Targets folate cycle, nuclear translocation, exercise mimetic
Humanin	mtDNA 16S rRNA	Cytoprotective but does not target folate or nuclear gene expression
CB4211 (analog)	Synthetic (CohBar)	Engineered for improved stability/longer half-life; Phase 1b completed

Retrograde Mitochondria-to-Nucleus Signaling Profiling

MOTS-c is used as a research probe to dissect retrograde mitochondria-to-nucleus signaling, in which a peptide encoded by the mitochondrial genome but translated in the cytoplasm translocates to the nucleus to remodel transcription. Studies using subcellular fractionation, chromatin-immunoprecipitation sequencing, and Nrf2-knockout cells have catalogued ~1,000 nuclear genes whose expression shifts under MOTS-c exposure, providing a research framework for understanding how mitochondrial bioenergetic state communicates with nuclear gene expression in models of metabolic stress, exercise, and aging.[3]

MOTS-c research spans metabolic disease, aging, exercise physiology, immunology, and bone health across 10+ indication categories:

1. Metabolic Disorders (Obesity/Diabetes) — Prevents HFD-induced obesity (body weight comparable to lean controls); reverses age/diet-induced insulin resistance; effective in T1D, T2D, and gestational diabetes models.[1][8]
2. Exercise Physiology — 22-month-old mice ran 2-fold longer (p=0.000002); skeletal muscle MOTS-c increased 11.9-fold during exercise in humans (n=10).[2]
3. Aging & Longevity — Endogenous levels decline with age; K14Q polymorphism associated with Japanese centenarian longevity; late-life treatment → median lifespan +6.4%.[2][7]
4. Cardiovascular Health — 55% reduction in vascular calcium content; 8% decrease in LV wall thickness in diabetic cardiomyopathy; prevention of heart failure.[12][13]
5. Bone Metabolism — Promotes osteoblast differentiation; inhibits osteoclastogenesis via RANKL suppression; significant BMD improvements in OVX osteoporosis model.[11]
6. Immunomodulation — MRSA sepsis survival 20% → 79% (pre-treatment); 50% → 100% (post-treatment); T-cell regulation (Treg vs Th1).[10]
7. Pain Management — Inflammatory and bone cancer pain via AMPK → MAPK-c-fos inhibition in spinal cord.[14]
8. Neuroprotection — Memory restoration via cell-penetrating analogs in Alzheimer's model; native MOTS-c does NOT cross BBB.[6]
9. Cold Adaptation — BAT thermogenesis via ERK → UCP1; maintained higher body temperature during acute cold exposure.[9]
10. Post-Menopausal Support — OVX mice: prevented weight gain, insulin resistance, and BAT whitening.[8]
11. Cancer — Ovarian cancer suppression via LARS1 ubiquitination; conflicting data on breast/prostate risk.[6]
12. Folate Cycle and AICAR Accumulation Profiling — Used as a research probe to investigate how inhibition of 5-methyltetrahydrofolate-dependent purine biosynthesis drives accumulation of AICAR (an AMP-mimetic) and the consequent direct activation of AMPK in skeletal-muscle and hepatocyte models, providing a research framework distinct from classical AMP-rise activation.[1]
13. Nrf2/ARE Antioxidant Gene-Network Investigation — Used in chromatin-immunoprecipitation and transcriptomic studies to map the ~1,000 nuclear genes activated when MOTS-c translocates to the nucleus and binds Antioxidant Response Elements via Nrf2 under metabolic-stress conditions. Provides a research handle on retrograde mitochondria-to-nucleus signaling.[3]
14. K14Q Polymorphism Comparative Studies — The naturally occurring m.1382A>C variant in the cationic tail (K14Q) is investigated for altered CK2 binding affinity and its association with exceptional longevity in Japanese population cohorts, providing a tool for research into MDP sequence variation and human aging biology.[7]

Comparative Research Context

Within the mitochondrial-bioenergetics research peptide family, MOTS-c is most directly compared with SS-31 (cardiolipin-binding mitochondrial-targeting peptide), NAD+ (substrate for SIRT1-driven mitochondrial-quality control), and 5-amino-1MQ (NNMT inhibitor altering adipocyte methylation pools). These cross-comparisons inform research designs that aim to dissect folate-AMPK-driven endpoints from mitochondrial-membrane stabilisation, sirtuin-driven biogenesis, and methylation-pool-driven phenotypes.